Anirban Maitra
Scientific Director of the Ahmed Center for Pancreatic Cancer Research at MD Anderson Cancer Ctr. Also a GI Pathologist. Tweets & opinions expressed are my own.
Last synced from Twitter 17m ago
UC San Diego doctors offer update on cancer prevention, genetic testing at La Jolla lecture series
La Jolla Light 10h 2 tweets
Inherited germline factors found to play bigger role than previously recognized
ZBED2 is an antagonist of Interferon Regulatory Factor 1 and modulates cell identity in pancreatic cancer
bioRxiv 7h 1 tweets
Lineage plasticity is a prominent feature of pancreatic ductal adenocarcinoma (PDA) cells, which can occur via deregulation of lineage-specifying transcription factors. Here, we show that the zinc finger protein ZBED2 is aberrantly expressed in PDA...
Anirban Maitra From lab : ZBED2 transcription factor is overexpressed in the aggressive (“squamous”) subtype of #PancreaticCancer, represses pancreatic progenitor identity & is an antagonist of interferon regulatory factor 1 (IRF1). 7h
Industries at a Glance: Ambulatory Health Care Services: NAICS 621
Bls.gov 7h 1 tweets
Anirban Maitra Over 400,000 healthcare jobs have been added over the last 12 months per What are “ambulatory health care services” 👇🏾 7h
Modern Pathology Welcomes New Editor-In-Chief
Prnewswire.com 13h 1 tweets
/PRNewswire/ -- The United States and Canadian Academy of Pathology is pleased to welcome George J. Netto, MD of The University of Alabama at Birmingham as the...
‘Endogenous T cells have high potential of treating blood, solid tumors’
M.koreabiomed.com 17h 1 tweets
A variety of adoptive T-cell therapeutic strategies has shown a remarkable remission rate exceeding 80 percent in certain areas of blood cancer treatm...
Anirban Maitra What are endogenous T cells (ETCs) for adoptive T cell Rx? An interview with 17h
Targeting dual signaling pathways in concert with immune checkpoints for the treatment of pancreatic cancer
bioRxiv 32h 1 tweets
Pancreatic cancer harbors a poor prognosis due to the lack of effective systemic therapies. Here we interrogated means to target key effector pathways down-stream from KRAS. We found that combination treatment with MEK and CDK4/6 inhibitors was...
Anirban Maitra Preclinical studies on combining CDK4/6 plus MEK inhibitors in #PancreaticCancer for facilitating #Immunotherapy. At least the targeted dual combination (minus checkpoint inhibitors) is being tested at 32h
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors - Full Text View - ClinicalTrials.gov
Clinicaltrials.gov 32h 1 tweets
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors - Full Text View.
Anirban Maitra Preclinical studies on combining CDK4/6 plus MEK inhibitors in #PancreaticCancer for facilitating #Immunotherapy. At least the targeted dual combination (minus checkpoint inhibitors) is being tested at 32h
Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement
U.S. Food and Drug Administration 32h 1 tweets
UPDATED PUBLIC PARTICIPATION INFORMATION: December 17, 2019: Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement
Anirban Maitra ODAC on PDAC. Dec 17, 2019. Lynparza for gBRCA mutant #PancreaticCancer 32h
Embryonal precursors of Wilms tumor
Science 32h 2 tweets
Many adult cancers arise from clonal expansions of mutant cells in normal tissue. These premalignant expansions are defined by somatic mutations shared by the cancers. Whether pediatric cancers originate in a similar way is unknown. Coorens et al....
Anirban Maitra Pediatric Wilms tumors arise from a premalignant bed within histologically normal renal tissues. Most fascinating - in bilateral tumors, phylogenetic analysis suggests clonal expansion before divergence of L/R renal primordia! Cc: 32h
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
Nature Medicine 5d 9 tweets
Analysis of fully clinically annotated and sequenced melanoma tumor samples collected before anti-PD1 treatment suggests that determinants of response differ on the basis of previous anti-CTLA4 therapy, and that tumor mutational burden may not be a...
Digging Deeper Into Survival Disparities in Pancreatic Cancer
Medpagetoday.com 40h 1 tweets
Outcome disparities disappear when adequate therapy is provided, study finds
Predicting pancreatic cancer treatment response with tumor classification
UNC Lineberger 40h 1 tweets
A new study by UNC Lineberger researchers could help predict how patients with pancreatic cancer will respond to certain treatments.
Genomic Medicine Year in Review: 2019
The American Journal of Human Genetics 38h 3 tweets
Research assessing the feasibility and value of incorporating genomic information into patient care is increasingly being reported. Published advances in the implementation of genomic medicine are reviewed on a monthly basis by the Genomic Medicine...
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low Dose Cyclophosphamide in Patients with Advanced Malignancies
Clinical Cancer Research 39h 2 tweets
Purpose: This first-in-human study assessed the safety, tolerability, dose-limiting toxicities (DLTs), antitumor activity, and pharmacokinetics of cemiplimab, a monoclonal anti-programmed cell death-1 (PD-1), as monotherapy and in combination with...
Anirban Maitra In case you are keeping (?losing) track of the various anti-aPD1s, here’s early Cemiplimab data in solid tumors. 39h
Lilly Announces New Leadership and Strategy in Oncology Research and Development
Eli Lilly and Company 42h 2 tweets
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Cut-price CAR-T cell therapies top India’s biotech agenda
Nature Biotechnology 3d 5 tweets
Indian startups plan affordable CAR-T therapies—first for domestic use, then for the global market.
New Pancreatic Cancer Tumor Categories May Inform Treatment Decisions
Allison Rosenzweig - Pancreatic Cancer Action Network 3d 1 tweets
New study published in Clinical Cancer Research describes test to classify pancreatic cancer tumors by their subtype, which may inform treatment decisions. The work was funded by a $2 million PanCAN research grant.
Archived News
Nccn.org 3d 1 tweets
Anirban Maitra The updated clinical practice guidelines on genetic testing in #BreastCancer #OvarianCancer & #PancreaticCancer have been published by Please see comments by & visit . 3d
A letter from Larry and Sergey
Google 3d 24 tweets
“We’ve never been ones to hold on to management roles when we think there’s a better way to run the company.”
CSHL wins TD Ready Challenge grant for organoid facility
Cold Spring Harbor Laboratory 4d 1 tweets
Cold Spring Harbor Laboratory (CSHL) has been awarded the TD Ready Challenge to support its new organoid facility. The TD Ready Challenge is an initiative by TD Bank to catalyze innovative solutions for a changing world. The grant provides financial...